IBRX

Immunitybio Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 2/10
  • Value↓ 0/10
Immunitybio sales and earnings growth
IBRX Growth
Fair
  • Revenue Y/Y↑ 351.53%
  • EPS Y/Y↓ -57.41%
  • FCF Y/Y↑ 20.59%
Immunitybio gross and profit margin trends
IBRX Profitability
Good
  • Gross margin ↑ 99.30%
  • EPS margin↓ -606.20%
  • ROIC 5Y↓ -41.65%
Immunitybio net debt vs free cash flow
IBRX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 3.1
  • Interest coverage↓ -6.6

Immunitybio stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks